← Back to Patent Explorer
US4021536A Expired / Lapsed US ⏱️ 0.0 years remaining

Magnesium-zirconium complexes useful as antiperspirants

Assignee: Reheis Co Inc
•
Filing: 1975-04-18
•
Granted: 1977-05-03
•
Expires: 1995-04-18
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Astringent compositions useful as antiperspirants are provided by forming a complex of a magnesium salt and an astringent zirconium compound, particularly zirconium oxy and hydroxy salts, such that the weight ratio of the zirconium content to the magnesium content in the complex expressed as the oxides will be in the range of about 30:1 to 1:1. The preferred amount of magnesium, expressed as the oxide, in an aqueous antiperspirant solution containing an effective amount of the complex will be greater than about 3 weight percent. Preferred compositions include complexes of magnesium-amino acid salts, such as magnesium glycinate, plus zirconyl hydroxy chloride in which the ratio of zirconium to magnesium is about 10:1 to 3:1 and the total content of magnesium plus zirconium is about 5 to 15 weight percent and preferably about 5 to 10 weight percent, both expressed as the oxides. Buffers such as urea, amino acids, salts of amino acids, etc. may also be included in the complexes to maintain a pH of at least about 3 in aqueous solutions of the complex. The various complexes of the invention may be used in conventional antiperspirant forms, including aqueous solutions, aerosol sprays, powder-in-oil aerosol sprays, creams, lotions, cream sticks, etc.

Inventors

  • 👤 Andrew M. Rubino

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-30 13:33
CPC Classifications
A; A61; A61Q; A61Q15/00; A61K; A61K8/00; A61K8/18; A61K8/19; A61K8/28; A61K8/30; A61K8/40; A61K8/44; A61K2800/00; A61K2800/40; A61K2800/58

Claims Analysis

Total Claims: 14
Claim 1
Independent Claim 122 words
An astringent, water-soluble complex formed by reacting in an aqueous solution: (a) a zirconium compound selected from trioxodizirconium hydroxy salts and the group having the general empirical formula: ZrO(OH).sub.2-nz B.sub.z wherein z may vary from about 0.9 to 2 and need not be an integer, n is the valence of B, 2-nz is greater than or equal to 0, and B is selected from the group consisting of halide, nitrate, sulfamate, sulfate and mixtures thereof; and (b) a magnesium compound comprising a magnesium-amino acid salt; said zirconium and magnesium compounds being present in amounts such that the weight ratio of zirconium to magnesium expressed in terms of the oxides as ZrO 2 /MgO is in the range of about 30:1 to 1:1.
Claim 2
Dependent Claim 122 words
An astringent, water-soluble complex formed by reacting in an aqueous solution: (a) a zirconium compound selected from trioxodizirconium hydroxy salts and the group having the general empirical formula: ZrO(OH).sub.2-nz B.sub.z wherein z may vary from about 0.9 to 2 and need not be an integer, n is the valence of B, 2-nz is greater than or equal to 0, and B is selected from the group consisting of halide, nitrate, sulfamate, sulfate and mixtures thereof; and (b) a magnesium compound comprising a magnesium-amino acid salt; said zirconium and magnesium compounds being present in amounts such that the weight ratio of zirconium to magnesium expressed in terms of the oxides as ZrO 2 /MgO is in the range of about 30:1 to 1:1.
Claim 3
Dependent Claim 65 words
An antiperspirant composition wherein the complex of claim 1 is dissolved in a non-toxic dermatologically acceptable solvent for said complex, the magnesium compound and the zirconium compound are present in amounts such that the total magnesium plus zirconium content expressed as the oxides is about 5 to 15 weight percent, and the magnesium content is greater than about 3 weight percent expressed as the oxide.
Claim 4
Dependent Claim 15 words
An astringent complex according to claim 1 wherein the zirconium compound comprises zirconium hydroxy chloride.
Claim 5
Dependent Claim 14 words
An astringent complex according to claim 1 wherein the magnesium compound comprises magnesium glycinate.
Claim 6
Dependent Claim 22 words
An astringent complex according to claim 1 wherein the magnesium compound is magnesium glycinate and the zirconium compound is zirconium hydroxy chloride.
Claim 7
Dependent Claim 23 words
An astringent complex according to claim 5 wherein the ZrO 2 /MgO weight ratio is in the range of about 10:1 to 3:1.
Claim 8
Dependent Claim 26 words
An astringent complex according to claim 5 wherein the total content of magnesium plus zirconium expressed as the oxides is about 5 to 10 weight percent.
Claim 9
Dependent Claim 35 words
An astringent complex according to claim 1 wherein the complex also includes a buffer to maintain the pH of a 5 to 15 weight percent aqueous solution of the complex at at least about 3.
Claim 10
Dependent Claim 21 words
A method of inhibiting perspiration comprising applying a perspiration inhibiting amount of the composition of claim 2 to the human axilla.
Claim 11
Dependent Claim 26 words
A method of inhibiting perspiration comprising applying a perspiration inhibiting amount of a solution or suspension of the complex of claim 5 to the human axilla.
Claim 12
Dependent Claim 47 words
A method of inhibiting perspiration comprising suspending the dried complex of claim 1 in an aerosol propellant, said complex being present in the aerosol propellant to an extent of about 1 to 6 weight percent of the propellant, and spraying the resulting suspension on the human axilla.
Claim 13
Dependent Claim 34 words
An astringent complex according to claim 1 wherein said zirconium compound also includes a source of zirconium selected from the group consisting of ammonium zirconyl carbonate, alkali metal zirconyl carbonate and basic zirconium gels.
Claim 14
Dependent Claim 32 words
An astringent complex according to claim 1 wherein said magnesium-amino acid salts comprise magnesium or magnesium-hydroxy salts of amino acids having an amino group for each carboxyl group in the acid molecule.

References Cited (Backward Citations)

US2236387A Cited
GB624120A Cited
US2814585A Cited
US2814584A Cited
US2854382A Cited
US3407254A Cited
US3405153A Cited
US3792068A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-05-02 1980-11-01 1981-05-03 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-05-02 1984-11-01 1985-05-03 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-05-02 1988-11-01 1989-05-03 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag